 |
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Fast, Simple and Ultra-Sensitive
Point-of-Care DiagnosticsVivacta is a Point-of-Care in vitro diagnostics company with innovative technology for rapid and quantitative near-patient immunoassay testing. Its lead product is a high sensitivity TSH assay for thyroid diagnosis.
Vivacta's piezofilm-based sensor technology has distinct benefits over alternative PoC detection technologies, such as photometric lateral flow. It is sensitive, possesses a wide dynamic range and has good precision. It also works with whole blood, thereby removing the need for a red cell separation step, reducing sample volumes. These benefits together deliver improved analytical performance, simple operation and faster time to result.
Guided by one of the most experienced boards of directors in the diagnostics industry, the company is privately held, with venture capital funding from leading bio-science investors.
The company is exploiting its technology through licensing arrangements with established diagnostic companies, as well as pharmaceutical businesses seeking combination diagnostic solutions.
Point-of-Care DiagnosticsVivacta is a Point-of-Care in vitro diagnostics company with innovative technology for rapid and quantitative near-patient immunoassay testing. Its lead product is a high sensitivity TSH assay for thyroid diagnosis.
Vivacta's piezofilm-based sensor technology has distinct benefits over alternative PoC detection technologies, such as photometric lateral flow. It is sensitive, possesses a wide dynamic range and has good precision. It also works with whole blood, thereby removing the need for a red cell separation step, reducing sample volumes. These benefits together deliver improved analytical performance, simple operation and faster time to result.
Guided by one of the most experienced boards of directors in the diagnostics industry, the company is privately held, with venture capital funding from leading bio-science investors.
The company is exploiting its technology through licensing arrangements with established diagnostic companies, as well as pharmaceutical businesses seeking combination diagnostic solutions.
Vivacta's piezofilm detection system consists of a bench-top, portable reader and a single use, disposable cartridge, which acts as the whole blood collection device. For more information and to view the system in use Click here
Events
Partnerships in Personalized Medicine Conference. 27th and 28th July, Munich. Read More
News
Vivacta raises $4.5 million to commercialise piezofilm technology
17 June 2009
Vivacta has closed a $4.5 million financing round that was fully subscribed by existing investors.
Read More